New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC…
Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with…
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560…
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to…
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001,…
FitSpresso is the perfect choice for those seeking an effective solution to achieve healthy weight loss. NEW YORK CITY, NY…
Driven by a network of more than 4,200 sites of care now using the AssistPoint® platform to manage and secure…
ALAMEDA, Calif., Jan. 9, 2025 /PRNewswire/ -- CellFE®, a leader in non-viral gene editing technology, and Syenex, a pioneer in…
TEMPE, Ariz., Jan. 9, 2025 /PRNewswire/ -- Economic activity in the hospital subsector grew in December for the 16th consecutive month…
Dr Jose-Carlos Gutiérrez-Ramos is the Chief Science Officer at Danaher Corporation. He has held senior drug discovery roles at Pfizer,…